Anzeige
Mehr »
Donnerstag, 26.06.2025 - Börsentäglich über 12.000 News
Blockbuster-Bohrergebnisse: Gold-Antimon-Fund in Nevada trifft geopolitischen Nerv
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PY7P | ISIN: US07373V1052 | Ticker-Symbol:
NASDAQ
25.06.25 | 21:59
16,760 US-Dollar
0,00 % 0,000
1-Jahres-Chart
BEAM THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
BEAM THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur BEAM THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
16.06.H.C. Wainwright reiterates buy rating on Beam Therapeutics stock7
13.06.Beam Therapeutics reports positive data from sickle cell therapy trial5
BEAM THERAPEUTICS Aktie jetzt für 0€ handeln
13.06.Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress238Updated Data from 17 Patients Consistent with Previously Presented Data; All Patients Treated with BEAM-101 Achieved Hemoglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to Patients...
► Artikel lesen
06.06.Beam Therapeutics Inc. - 8-K, Current Report5
03.06.Beam Therapeutics Announces Orphan Drug Designation For BEAM-101282WASHINGTON (dpa-AFX) - Beam Therapeutics (BEAM) announced that the FDA has granted orphan drug designation to BEAM-101, an investigational genetically modified cell therapy for the treatment...
► Artikel lesen
03.06.Beam Therapeutics' BEAM-101 receives FDA orphan drug status for SCD treatment2
29.05.Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)1.006CAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...
► Artikel lesen
14.05.Beam Therapeutics to Highlight New Data from BEAM-101 Program in Sickle Cell Disease at European Hematology Association (EHA) 2025 Congress19
12.05.Beam Therapeutics granted FDA's Regenerative Medicine Advanced Therapy designation2
12.05.Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)303CAMBRIDGE, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...
► Artikel lesen
07.05.10 Analysts Assess Beam Therapeutics: What You Need To Know7
06.05.Why Beam Therapeutics Stock Tanked on Tuesday5
06.05.Beam Therapeutics GAAP EPS of -$1.24 misses by $0.05, revenue of $7.47M misses by $7.21M6
06.05.Beam Therapeutics Inc. Q1 Loss Increases, Misses Estimates354WASHINGTON (dpa-AFX) - Beam Therapeutics Inc. (BEAM) reported Loss for its first quarter that increased from last year and missed the Street estimates.The company's bottom line totaled -$109.27...
► Artikel lesen
06.05.Beam Therapeutics Inc. - 10-Q, Quarterly Report2
06.05.Beam Therapeutics Inc. - 8-K, Current Report3
25.04.Beam Therapeutics to Report Q1 Earnings: What's in the Cards?6
25.04.Cathie Wood's ARK Sells Adaptive Biotech, Buys Beam Therapeutics Stock9
11.04.Cathie Wood's ARK ETF focuses on Beam Therapeutics, Coinbase stock40
07.04.Beam Therapeutics Presents Biomarker Data For BEAM-302 Gene Therapy For Inherited Disease3
Weiter >>
71 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1